It has been reported that gene expression directed by the long terminal repeat of Rous sarcoma virus (RSV) is trans activated by a protein encoded in an alternate reading frame within the RSV gag gene (S. Broome and W. Gilbert, Cell 40:537-546, 1985). We have made specific mutations to test the role of the putative transcriptional activator in RSV replication. Termination codons were created within the alternate reading frame coding for the trans activator, and the mutations were introduced into an infectious RSV plasmid. We were unable to demonstrate specific trans activation of the RSV long terminal repeat by either wild-type or mutant RSV plasmids in transient cotransfection assays. Experiments using mutant or wild-type RSV-infected chick embryo fibroblasts indicated that the proposed RSV transcriptional activator was not required for viral replication or transformation and did not increase steady-state levels of viral RNA.
It has been reported that gene expression directed by the long terminal repeat of Rous sarcoma virus (RSV) is trans activated by a protein encoded in an alternate reading frame within the RSV gag gene (S. Broome and W. Gilbert, Cell 40: [537] [538] [539] [540] [541] [542] [543] [544] [545] [546] 1985) . We have made specific mutations to test the role of the putative transcriptional activator in RSV replication. Termination codons were created within the alternate reading frame coding for the trans activator, and the mutations were introduced into an infectious RSV plasmid. We were unable to demonstrate specific trans activation of the RSV long terminal repeat by either wild-type or mutant RSV plasmids in transient cotransfection assays. Experiments using mutant or wild-type RSV-infected chick embryo fibroblasts indicated that the proposed RSV transcriptional activator was not required for viral replication or transformation and did not increase steady-state levels of viral RNA.
A number of retroviruses have been shown to encode proteins which can activate expression of viral genes. These include the human T-cell lymphotropic virus types I and II (HTLV-I and HTLV-II) (5, 30) , human immunodeficiency virus (31) , bovine leukemia virus (24) , equine infectious anemia virus (28) , and visna virus (15) . These transcriptional activator proteins are encoded in small open reading frames overlapping the viral structural genes and are translated from subgenomic spliced mRNAs (2, 18, 27, 29) . The transactivator proteins of HTLV-I, HTLV-II, and human immunodeficiency virus have been shown to be essential for viral replication (5, 9, 11) . Although these transcriptional activators are encoded in the 3' half of the viral genomes, they act on the 5' long terminal repeats (LTRs) . Transcriptional activation by the HTLV-I, HTLV-II, and bovine leukemia virus proteins has been shown to require enhancer sequences upstream of the mRNA cap site in the U3 region of the viral LTR (23, 30) . In contrast, the sequences responsive to the human immunodeficiency virus transcriptional activator are 3' of the mRNA cap site in the R region of the LTR (21) .
It has been proposed by Broome and Gilbert (3) that Rous sarcoma virus (RSV) also encodes a transcriptional activator protein. The presence of a trans activator was inferred from the ability of RSV plasmids to increase the expression of cotransfected genes in transient assays. Cotransfection of a rat preproinsulin gene with RSV plasmids resulted in a 10-fold increase in stable insulin mRNA. Expression of an insulin plasmid under control of the RSV LTR was also stimulated by cotransfection with RSV plasmids. The RSV sequences responsible for trans activation of the preproinsulin promoter were localized to the p19-plO region of the gag gene by deletion mutagenesis. Analysis of frameshift mutations in the gag gene suggested that the trans-activator protein may be encoded in an alternate reading frame and translated from a spliced, subgenomic mRNA. Evidence for such an mRNA came from primer extension and S1 nuclease analyses, which suggested a new splice acceptor at nucleotide 681. The mRNA was proposed to use the known RSV splice donor at nucleotide 397. However, no cDNA corresponding to this new mRNA has been described, and its product has not been detected. The RSV sequences required for response to the trans activator were roughly localized upstream of the cap site in the U3 region of the RSV LTR (3) .
Among avian retroviruses, only RSV has been reported to encode a transcriptional activator. The presence of such a trans activator would have important implications for tumor virus-induced transformation and for replication of this group of viruses. We have been interested in mechanisms of gene regulation in avian retroviruses, including RSV. We have recently localized a cis-acting enhancer within the gag genes of avian retroviruses by using a transient chloramphenicol acetyltransferase (CAT) assay system (1, 4) . The sequences required for enhancement of CAT activity and cat mRNA levels include most of the coding sequences for the proposed RSV trans activator (Fig. 1A) . However, the enhancement of CAT activity is not due to a trans-acting gag protein. The same frameshift mutations that abolished trans activation of insulin gene constructs in the cotransfection assays of Broome and Gilbert (3) did not reduce enhancer activity in our CAT assays (1) .
To investigate the significance of the proposed RSV transactivator protein, we used site-directed mutagenesis to create termination codons within the alternate reading frame coding for the trans activator. RSV LTR (12) . Three plasmids derived from pRSVcat were a gift from S. Arrigo and have been described previously (1) . pRSV(gag)cat contains a 617-nucleotide BamHI-to-BcII gag gene fragment (nucleotides 533 to 1659) from SchmidtRuppin A RSV cloned into the BamHI site downstream of the polyadenylation site for the cat gene transcript in pRSV cat. In pRSV-Ecat and pRSV-E(gag)cat, most of the RSV LTR enhancer has been removed by deletion of an MstIIto-SphI fragment, deleting sequences upstream of nucleotide -139.
Site-directed mutagenesis. Site-directed mutagenesis was performed as described by Zoller and Smith (36), using a single-stranded M13 bacteriophage DNA template and synthetic oligonucleotides. The template for mutagenesis was a 1,384-nucleotide BamHI gag gene fragment from Pr-C RSV (nucleotides 533 to 1917) cloned into the BamHI site of M13mpl8. Double-stranded replicative-form DNAs were isolated from mutant clones, and the 1,263-nucleotide SacII gag gene fragments containing the mutations were cloned into the SacII site of pATV8KASacII to generate pATV8K mutants 3 and 4. The mutant pATV8K plasmids were sequenced by the dideoxy method described by Sanger et al. (25) CAT assay. Approximately 48 h after DNA transfection, cells were lysed and assayed for CAT activity as described by Gorman et al. (13) and modified by Arrigo et al. (1) .
Reverse transcriptase assay. Duplicate samples (50 ,ul) of culture medium from plates of RSV-transformed CEFs were assayed for reverse transcriptase activity as described by Kane and Beemon (17) .
Focus formation assay. KpnI-cut and ligated DNAs (100 ng) were transfected into 60-mm plates containing 5 x 105 CEFs. On the following day, the culture medium was removed and 8 ml of 0.7% agar overlay medium was added to prevent virus spread, as described by Vogt (34) . The plates were overlaid every 4 days with 5 to 8 ml of agar overlay medium.
RNA isolation and assay. Plates (9 cm) of infected CEFs were trypsinized, and one-half of the cells was used to prepare cellular RNA. The cells were washed once with phosphate-buffered saline, pelleted by centrifugation for 5 min at 200 x g, and then lysed by the addition of guanidinium isothiocyanate buffer. Total cellular RNA was purified by pelleting through a 5.7 M CsCl cushion as described by Chirgwin et al. (6) .
RNase protection assays were performed as described by
Melton et al. (20) . The riboprobe template was a gift from S. Arrigo and contained a 585-nucleotide EcoRI-to-BamHI DNA fragment from pATV8K cloned into pGem2 (S. Arrigo and K. Beemon, Mol. Cell. Biol., in press). In vitro transcription of the EcoRI-digested template produced a 626-nucleotide RNA probe spanning the RSV splice donor and RNA cap site, which allowed simultaneous quantitation of spliced and unspliced RNAs. Protected RNA fragments were fractionated on a 6% acrylamide-urea sequencing gel (19) , and RNA bands were excised and quantitated by scintillation counting. DNA quantitation. One-half of the cells from each infected plate was used to quantitate viral DNA as previously described (4). Cellular DNAs were digested with EcoRI and BamHI, electrophoresed on a 0.5% agarose gel, and blotted to nitrocellulose (32) . The blots were hybridized to a 32P-labeled (10) SacI-to-PvuI pATV8K v-src fragment (nucleotides 6870 to 9184). Viral DNA bands were quantitated by densitometry of the resultant autoradiogram.
RESULTS
Mutagenesis of the putative trans activator. It was proposed by Broome and Gilbert (3) that RSV encodes a transcriptional activator from an alternate reading frame overlapping the gag gene sequences for p19, p2, and plO (3). It was suggested that the message for the trans activator is spliced from the known RSV splice donor at nucleotide 397 to a new splice acceptor at nucleotide 681. This spliced mRNA would direct translation from the Pr76gag initiation codon into the alternate reading frame. The proposed splice donor and splice acceptor for the trans-activator mRNA are diagrammed in Fig. 1A . Upon inspection of the RSV sequence in this region, we observed another possible splice acceptor sequence 24 bases downstream from the proposed splice acceptor. The trans-activator reading frame encodes a cluster of basic amino acids which could be part of a DNAbinding domain. This basic cluster is preceded by a methionine (amino acid 42) encoded by the first AUG codon downstream of the proposed splice acceptor. The experiments of Broome and Gilbert (3) did not rule out the possibility that translation of the trans activator begins at this methionine. Further, the 5' border of the coding region for the basic cluster of amino acids, which is just upstream of the NarI site, colocalizes with the 5' boundary of the previously described gag enhancer (4) shown in Fig. 1A .
To study the role of the proposed trans activator in RSV replication, we first sought to inactivate any protein encoded in its reading frame. Oligonucleotide-directed mutagenesis was used to create termination codons at two different sites in the putative trans activator. In mutant 3, the termination codon was generated at the site of the serine-19 codon at nucleotide 717, which is downstream of the proposed splice acceptor (Fig.1) . In mutant 4, the leucine-56 codon at nucleotide 828, which is downstream of the NarI site, was converted to a UAG termination codon (Fig. 1) . The synthetic oligonucleotides used to make these mutants are shown at the bottom of Fig. 1B . Neither mutation altered the amino acid sequence of the pl9gag protein (Fig. 1B) 4 3 assayed 7 days later by using reverse transcriptase assays (17) . No significant differences in reverse transcriptase activity between mutant and wild-type viruses were seen ( Table 2) . Next, dilutions of culture medium containing equivalent reverse transcriptase units of mutant or wild-type virus were used to infect new plates of CEFs. Equal volumes of culture supernatant were assayed 5 days later for reverse transcriptase activity. Again, no differences were seen between mutant and wild-type viruses (Table 2) . These experiments show that neither mutation reduced viral replication or infectivity. Steady-state levels of viral RNA. Broome and Gilbert (3) demonstrated an apparent increase in steady-state levels of RNA transcribed from the RSV LTR after cotransfection with RSV plasmids. This increase was attributed to trans activation by the proposed gag-encoded transcriptional activator. We therefore assayed steady-state levels of viral RNA in cells infected with either wild-type or mutant RSV. Plates of infected cells were trypsinized, and one-half of the cells was used to prepare cellular RNA as previously described (6). RNase-protection assays were performed with mutant and wild-type RNA samples (20) . The riboprobe template contained a 585-base-pair EcoRI-to-BamHI fragment from pATV8K. The 626-base antisense RNA probe transcribed from this template spans the RSV splice donor and the mRNA cap site, allowing quantitation of both spliced and unspliced RNA (Fig. 2) .The ratios of unspliced RNA to spliced RNA were identical in mutant and wild-type RSVinfected CEFs. The relatively low levels of spliced RNA have been seen by others in CEFs infected with the Pr-C strain of RSV (33 transforming potential of the viral mutants. Wild-type or mutant pATV8K DNAs (100 ng) were transfected into CEFs. On the following day, agar overlays were added to the plates to prevent viral spread. Foci of transformed cells were counted after 7 to 10 days. Both mutant DNAs transformed CEFs with the same efficiency and at the same rate as did the wild-type RSV DNA (Table 4) . Thus, we found no evidence that the RSV transcriptional activator is necessary for transformation of CEFs.
DISCUSSION
The data presented here show that the RSV transcriptional activator proposed by Broome and Gilbert (3) was not required for RSV replication or for transformation. We found no difference in expression of viral RNA between wild-type virus and two mutants containing termination codons within the reading frame coding for the putative trans activator. This is in contrast to the results seen with other viruses whose transcriptional activators are essential for viral replication (5, 9).
Broome and Gilbert (3) reported that the RSV trans activator increased expression from the RSV LTR, as well as from a heterologous preproinsulin promoter. Evidence for trans activation of the RSV LTR came from cotransfection experiments in which an RSV LTR-insulin target plasmid was apparently activated in trans by an RSV plasmid. However, the increased levels of LTR-insulin RNA were not quantitated and were not shown to be due to an increase in transcription. In our cotransfection assays, we used conditions similar to those of Broome and Gilbert (3), including the same cell type (NIH 3T3 cells) and the same transfection protocol. Therefore, our inability to demonstrate trans activation of the RSV LTR by a Pr-C RSV plasmid was unexpected. The two-to threefold apparent activation by mutant and wild-type RSV plasmids seen in our assays appeared similar to the level of activation observed by Broome and Gilbert (3). However, we found that cotransfection with pBR322 alone also increased expression of the RSV LTR threefold in mouse 3T3 cells. Therefore, our apparent activation was not significant. Further, no difference was seen between wild-type and trans-activator mutants in this assay.
Although our data suggest that vector sequences alone could have been responsible for the trans activation observed by Broome and Gilbert (3), other explanations are possible. Recombination between cotransfected DNAs may have increased expression by providing additional potent enhancers in cis. Since the LTR-insulin target plasmid used by Broome and Gilbert (3) was cut with restriction enzymes prior to transfection, this may have facilitated recombination. Because the experiments reported by Broome and Gilbert (3) were not controlled for the amount of viral DNA present in transfected cells, differences in the initial DNA concentrations or efficiences of DNA uptake cannot be ruled out. Cullen et al. (8) have shown that retrovirus infection of avian cells enhances expression of transfected preproinsulin plasmids, but it was proposed that this activation is due to an increase in the uptake of transfected DNA.
trans Activation of the RSV LTR by RSV proteins has not been confirmed by other workers. Norton and Coffin (22) looked for trans activation of a P-galactosidase gene under control of the RSV LTR. Expression of ,-galactosidase was found to be substantially lower in RSV-infected turkey cells than in uninfected cells. Cotransfection of the ,-galactosidase plasmid with a pATV8 plasmid also led to a decrease in ,-galactosidase activity (22) .
Most of the evidence presented by Broome 
